Search - tctmd.com

Displaying 641 - 660 of 704

Sort: Relevancy | Date

News Daily News

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Michael O'Riordan

April 11, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

L.A. McKeown

March 09, 2017

News Daily News

Both Appropriate and Inappropriate ICD Shocks Prompt Substantial Use of Healthcare Resources

Todd Neale

February 16, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Daily News

Noncardiac Chest Pain After Acute MI Common and ‘Just as Scary’: Why Cardiologists Should Care

Shelley Wood

January 12, 2017

News Daily News

Perioperative MACCE Rate Falls but Ischemic Stroke Rises Among Noncardiac Surgery Patients

Yael L. Maxwell

January 04, 2017

News Daily News

Not Following NOAC Dosing Instructions Tied to Worse Clinical Outcomes

Todd Neale

December 12, 2016

News Daily News

Benefits of PCI for STEMI Not Attenuated in Patients With a Cancer History

L.A. McKeown

December 01, 2016

News Conference News AHA 2016

Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

Shelley Wood

November 13, 2016

News Conference News AHA 2016

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Yael L. Maxwell

November 13, 2016

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

News Industry News

Sudy Indicates PCI Of NIRS-Defined Lipid-Rich Plaque Is Safe And Not Associated With A Greater Incidence Of Adverse Outcomes Compared To PCI of Non Lipid-Rich Plaque

November 01, 2016

News Daily News

Fallout From Rehospitalization After Acute MI May Extend Beyond Economics

Yael L. Maxwell

October 28, 2016

News Daily News

Cardiac Rehab: No Impact on Quality of Life for Acute MI Patients?

Yael L. Maxwell

October 27, 2016

Advertisement

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

Both Appropriate and Inappropriate ICD Shocks Prompt Substantial Use of Healthcare Resources

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Noncardiac Chest Pain After Acute MI Common and ‘Just as Scary’: Why Cardiologists Should Care

Perioperative MACCE Rate Falls but Ischemic Stroke Rises Among Noncardiac Surgery Patients

Not Following NOAC Dosing Instructions Tied to Worse Clinical Outcomes

Benefits of PCI for STEMI Not Attenuated in Patients With a Cancer History

Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Sudy Indicates PCI Of NIRS-Defined Lipid-Rich Plaque Is Safe And Not Associated With A Greater Incidence Of Adverse Outcomes Compared To PCI of Non Lipid-Rich Plaque

Fallout From Rehospitalization After Acute MI May Extend Beyond Economics

Cardiac Rehab: No Impact on Quality of Life for Acute MI Patients?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content